Table 2: Biological drugs targeting molecules relevant for atopic/allergic disease pathomechanisms.
Target | Indication | Drug | |
IL-5 receptor (CD125) | Asthma | Benralizumab | |
Inhibits the dimerization of IL-13Rα1 and IL-4Rα | Asthma + AD | Lebrikizumab | * |
IL-5 | Asthma | Mepolizumab | |
IL-5 Rα | Asthma | Reslizumab | |
IgE | Asthma + Urticaria | Omalizumab | |
IL-4 Rα subunit | AD, Asthma, CRSwNP | Dupilumab | |
IL-9 | Asthma | Enokizumab | * |
IL-13 | AD | Tralokinumab | |
IL-33 | AD | Etokimab | |
IL-31 receptor A | AD | Nemolizumab | |
TSLP | Tezepelumab | Tezepelumab | |
IgE | Chronic urticaria | Ligelizumab | |
IgE | Chronic urticaria, Asthma, CRSwNP | Omalizumab | |
Lectin 8 | Asthma | Lirentelimab | |
Inhibits JAK1 and JAK2 | AD | Baricitinib | |
JAK1 inhibitor | AD | Upadacitinib | |
JAK1 inhibitor | AD | Abrocitinib | |
A CRTH2 antagonist | Th2-mediated inflammation | AMG853 | * |
A CRTH2 antagonist | Th2-mediated inflammation | OC000459 | * |
A CRTH2 antagonist | Th2-mediated inflammation | BI671800 | * |
Inhibitor of GSNOR | Th2-mediated inflammation | N6022 | * |
Plasma kallikrein | Hereditary angioedema | Lanadelumab | |
Adapted from Guelsen et al., 202030, modified and updated 31. *Studies ongoing